MET is required for the recruitment of anti-tumoural neutrophils by Finisguerra, Veronica et al.
LETTER
doi:10.1038/nature14407
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Mutations or amplification of the MET proto-oncogene are
involved in the pathogenesis of several tumours1–4, which rely on
the constitutive engagement of this pathway for their growth and
survival1,5. However, MET is expressed not only by cancer cells but
also by tumour-associated stromal cells, although its precise role in
this compartment is not well characterized6–11. Here we show that
MET is required for neutrophil chemoattraction and cytotoxicity
in response to its ligand hepatocyte growth factor (HGF). Met
deletion in mouse neutrophils enhances tumour growth andmeta-
stasis. This phenotype correlates with reduced neutrophil infiltra-
tion to both the primary tumour and metastatic sites. Similarly,
Met is necessary for neutrophil transudation during colitis, skin
rash or peritonitis. Mechanistically, Met is induced by tumour-
derived tumour necrosis factor (TNF)-a or other inflammatory
stimuli in both mouse and human neutrophils. This induction is
instrumental for neutrophil transmigration across an activated
endothelium and for inducible nitric oxide synthase production
upon HGF stimulation. Consequently, HGF/MET-dependent
nitric oxide release by neutrophils promotes cancer cell killing,
which abates tumour growth and metastasis. After systemic
administration of a MET kinase inhibitor, we prove that the thera-
peutic benefit of MET targeting in cancer cells is partly countered
by the pro-tumoural effect arising from MET blockade in neutro-
phils. Our work identifies an unprecedented role of MET in neu-
trophils, suggests a potential ‘Achilles’ heel’ of MET-targeted
therapies in cancer, and supports the rationale for evaluating
anti-MET drugs in certain inflammatory diseases.
To ensureMet deletion in the immune system only, we took advant-
age of the Tie2:Cre deleter that excises floxed genes in both bone
marrow and endothelial cells12, andwe reconstituted lethally irradiated
C57BL/6 wild-type (WT) mice with bone marrow cells from
Tie2;Metwt/wt (WT) or Tie2;Metfl/fl (knockout (KO)) mice (Extended
Data Fig. 2a), producing WTRWT or KORWT mice, respectively.
Compared to WTRWT controls, both growth and metastatic burden
of subcutaneous LLC lung carcinomas were boosted inKORWTmice
(Fig. 1a–g), with reduced tumour apoptosis and necrosis, increased
proliferation, but comparable vessel parameters and hypoxia
(Extended Data Fig. 2b–r). A similar induction in tumour growth
and metastasis was observed in non-irradiated KO versus WT mice
(Extended Data Fig. 2s–u), but tumour growth, as well as the vascular
features, were comparable in WTRWT versus WTRKO chimaeras,
displaying Met deletion in endothelial cells only (Extended Data Fig.
2o–r, v). Thus, Met deletion in immune cells favours cancer growth
and metastasis.
Blood counts and percentage of circulating blood cell subsets did not
change in WTRWT and KORWT mice, either at baseline or upon
LLC tumour engraftment (Extended Data Fig. 3a–e and Extended
Data Tables 1, 2).Notably, KORWTmice displayed reduced numbers
of tumour-infiltrating CD451 leukocytes and, among all the different
subpopulations, only Ly6G1 tumour-associated neutrophils (TANs)
were strongly reduced in KORWTversusWTRWTmice at any time
point (Fig. 1h–j and Extended Data Fig. 3f–k). Similarly, lungs from
KORWT tumour-bearing mice contained fewer CD451 leukocytes
with decreased Ly6G1 neutrophil infiltration, whereas the number of
F4/801 macrophages was comparable (Fig. 1k–m and Extended Data
Fig. 3l, m). Furthermore, reconstitution of Met in neutrophils only13
(Extended Data Fig. 4a, b) was sufficient to rescue their recruitment
and to hinder tumour growth and metastasis in KORWT mice
(Fig. 1n–q). Vice versa, restricted deletion of Met in neutrophils
(Mrp8;Metfl/fl) by the neutrophil-specific Mrp8:Cre line13 (Extended
Data Fig. 4c, d) led to enhanced tumour growth and dissemination,
and marked TAN reduction, as in KORWT chimaeras (Fig. 1r–u and
Extended Data Fig. 4e). These results indicate thatMET is required for
recruiting anti-tumoural neutrophils.
To extend our findings to other tumour types, we proved that Met
deletion in the haematopoietic system increased the growth of (1)
orthotopic T241 fibrosarcomas and B16F10 melanomas, (2) spontan-
eous mammary tumours in MMTV-PyMT1 transgenic mice, (3)
H-Ras(G12V)- and c-Myc-driven hepatocellular carcinomas (HCCs),
and (4) chemically induced colorectal cancers (CRCs) (Fig. 2a–j and
Extended Data Fig. 5a, b). Furthermore, lung colonization of B16F10
melanoma cells (from either the primary tumour or after cancer
cell intravenous injection) and of MMTV-PyMT1 breast tumours
was boosted in Met KO chimaeras (Fig. 2k, l and Extended Data
Fig. 5c). In all these tumour types, Met KO TANs were fewer than
WT TANs (Fig. 2m and Extended Data Fig. 5d, e). Interestingly,
during chronic bowel inflammation (preceding CRC formation), neu-
trophil but notmacrophage infiltration of the colonwas also abated by
haematopoietic Met deletion, but this reduction did not impinge on
colitis severity (Extended Data Fig. 5f–i). B16F10 melanomas and
HCCs displayed enhanced tumour growth (and metastasization) as
well as reducedTAN infiltration inMrp8;Metfl/fl versusMrp8;Metwt/wt
mice (Fig. 2n–q). Conversely, orthotopic Panc02 carcinomas grew
and metastasized similarly in both WTRWT and KORWT mice,
and TAN infiltration did not change (Extended Data Fig. 5j–l).
However, these tumours produced little HGF compared to LLC
tumours (Extended Data Fig. 5m, n). In general, plasma and intratu-
mour HGF did not differ between genotypes (Extended Data
Fig. 5o, p). In sum, Met deficiency in neutrophils promotes the pro-
gression of different (HGF-secreting) tumours.
Systemic treatment ofWTmice carrying B16F10melanomas (which
are dependent on MET14) with three different MET tyrosine-kinase
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inhibitors (PF-04217903, INCB28060 and JNJ-38877605), strongly
reduced TAN recruitment (Extended Data Fig. 5q). We then com-
pared MET silencing in cancer cells versus systemic MET inhibition.
Systemic administration of PF-04217903 decreased the weight and
volume of B16F10 melanomas by 36% and 54%, respectively. Instead,
MET knockdown in cancer cells only, led to 58% and 75% inhibition
of tumour growth and volume (Fig. 2r, s and Extended Data Fig. 5r).
However, the combination of these two strategies was not synergic
but dampened tumour inhibition to the same level as observed with
PF-04217903 alone (Fig. 2r, s). TAN inhibition by PF-04217903 was
comparable in bothMet-silenced and scrambled B16F10 melanomas
(Fig. 2t). These data unveil how the therapeutic benefit of systemic
MET inhibition is partly blunted by the blockade of anti-tumoural
neutrophils.
To date, MET expression in neutrophils has been poorly documen-
ted11. We thus measured MET levels in circulating or tumour-infilt-
rating neutrophils. Circulating Ly6G1 cells from healthy mice
expressed low MET, but these levels were increased in circulating
neutrophils from LLC-tumour-bearing mice and even further in
TANs (Fig. 3a, b and Extended Data Fig. 6a). Similarly, neutrophils
isolated from non-small-cell lung tumours displayed much higher
MET levels than in the healthy tissue (Fig. 3c).
Co-culture with interleukin (IL)-1a pre-activated endothelium
as well as stimulation with tumour- or cancer-cell-conditioned
medium (TCM or CCM, respectively) promoted MET expression
in both mouse and human neutrophils (Fig. 3d–g). In a biased
approach15–17, we found that TNF-a and lipopolysaccharide (LPS)
(but not IL-1a, HGF, or hypoxia) induced MET expression in
both mouse and human neutrophils (Fig. 3h and Extended Data
Fig. 6b–e; data not shown). TNF-a-mediated MET induction
required TNFR1 and subsequent nuclear factor (NF)-kB activation
(Fig. 3i–k). TNF-a alone was not able to trigger either MET
phosphorylation or HGF release in neutrophils (Extended Data
Fig. 6f–h).
Silencing of endothelial-cell-borne TNF-a (which is 250-fold
increased upon stimulation with IL-1a; Extended Data Fig. 6i), knock-
out of neutrophil-borne TNFR1 (but not of TNFR2), and pharmaco-
logical blockade of TNF-a with the TNF-a-trap Enbrel, prevented
MET induction in mouse or human neutrophils upon co-culture with
activated endothelial cells or exposure to TCM/CCM (Fig. 3l and
Extended Data Fig. 6j–m). Finally, systemic administration of Enbrel
in LLC-tumour-bearing mice diminished MET expression in neutro-
phils as well, resulting in their reduced recruitment to the tumour
(Fig. 3m, n). AlthoughMET is scarcely expressed in naive neutrophils,
it is strongly induced by inflammatory stimuli.
Mechanistically, impaired TAN accumulation after Met inactiva-
tion was not due to cell death as assessed in LLC tumours and in
culture, both at baseline and under LPS stimulation, with or without
HGF (Extended Data Fig. 7a–e), but rather to a defect in neutrophil
recruitment from the blood. Indeed, also in the case of acute inflam-
mation,Met KO neutrophils displayed reduced exudation to the skin
or to the peritoneal cavity (Fig. 4a–d and Extended Data Fig. 8a, b).
Macrophage and lymphocyte recruitment did not change (Fig. 4d and
Extended Data Fig. 8c, d). Vice versa, recombinant HGF recruitedWT
neutrophils inside subcutaneous air pouches with similar efficacy to
the neutrophil chemoattractant CXCL1 (Fig. 4e and Extended Data
Fig. 8e). In contrast, Met KO neutrophils did not migrate towards
HGF, although their response to CXCL1 was preserved (Fig. 4e and
Extended Data Fig. 8e). Mirroring this approach, an anti-HGF block-
ing antibody18 prevented neutrophil infiltration to tumours and
inflamed skin (Fig. 4f).
We then tested the relevance of MET for neutrophil migration.
Stimulation of WT neutrophils with HGF promoted their adhesion
and chemotaxis through an activated endothelium whereas Met KO
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Figure 1 | Met deficiency inhibits neutrophil
recruitment to tumour and metastatic site.
a–g, LLC tumour growth (a), weight (b), lung
macrometastases (c), metastatic area
(d), representative images of haematoxylin and
eosin (H&E)-stained lung sections (e, f), and
metastatic index (g) in WTRWT and KORWT
chimaeras. Data combine three independent
experiments; total mice: WTRWT,23;
KORWT, 26. h–m, Neutrophil quantification and
representative images on Ly6G-stained LLC
tumour sections (h–j) or on lung sections from
tumour-free and tumour-bearing mice
(k) represented in l,m. Data in h are representative
of four independent experiments (6 mice per
condition per experiment). Data in k combine
three independent experiments; total mice:
tumour-free, 10 per condition; tumour-bearing, 15
per condition. n–q, LLC tumour growth
(n), tumour weight (o), lung macrometastases
(p), and TAN quantification (q) in WTRWT and
KORWT control chimaeras (Mrp8:Empty) or
upon neutrophil-specificMet reconstitution
(Mrp8:Met). Data combine two independent
experiments; totalmice, 10 per condition. r–u, LLC
tumour growth (r), tumour weight (s), lung
macrometastases (t), and TAN quantification
(u) upon neutrophil-specificMet deletion
(Mrp8;Metfl/fl) and in controls (Mrp8;Metwt/wt).
Data combine two independent experiments; total
mice, 13 per condition. *P, 0.05. Scale bars:
100mm (e, f); 50mm (i, j, l, m). Graphs show
mean6 standard error of the mean (s.e.m.).
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neutrophils (displaying an 85% reduction in MET protein levels com-
pared to WT; Extended Data Fig. 2a) completely lost this response
(Fig. 4g, h and Extended Data Fig. 8f). In line with this, TCM (contain-
ing 2.66 0.3 ngml21 HGF) promoted transendothelial migration of
WT neutrophils, but its effect was 43% lower onMet KO neutrophils
(Fig. 4i). Upon HGF neutralization, WT neutrophils responded to
TCM only partially, as did Met KO neutrophils (Fig. 4i). Neither
HGF nor TCM influenced neutrophil behaviour on non-activated
endothelial cells or bare membranes (Extended Data Fig. 8f–h).
Hence, HGF-mediated MET activation is required for neutrophil
transendothelial migration to the inflammatory site.
Once migrated inside the tumour, N1 or N2 neutrophils can inhibit
or favour tumour progression, respectively19. Among the N1 and N2
genes, only the expression of the N1 marker inducible nitric oxide
synthase (Nos2, also known as iNos) was lower in Met KO versus
WT TANs but similar in macrophages (Fig. 4j and Extended Data
Fig. 8i). Compared to WTRWT mice, tumours harvested from
KORWT mice displayed reduced nitric oxide (NO) production and
3-nitrotyrosine (3NT) formation, a sign of NO-mediated cell damage
(Fig. 4k–n). In vitro,MetKOTANs had lower cancer-cell-killing capa-
city than WT TANs; iNOS inhibition by NG-monomethyl-L-arginine
(L-NMMA)blunted this difference (Fig. 4o andExtendedData Fig. 8j).
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Figure 2 | Met deficiency in haematopoietic cells fosters progression of
several tumour types. a–c, Growth of T241 fibrosarcomas (a), B16F10
melanomas (b) and PyMT-driven breast tumours (c). Data in a, b combine two
independent experiments; total mice, 14 per condition (a); 8 per condition
(b). Data in c combine three independent experiments; total mice:
WTRPyMT, 13; KORPyMT, 16. d–g, Liver weight (d), nodules (e), and
images (f, g) after H-Ras(G12V)/c-Myc-driven HCC (n5 4 mice per
condition). h–j, Quantification (h) on H&E-stained bowel sections (i, j) of
colon adenomas (yellow arrowheads) and carcinomas (red arrowheads) after
administration of azoxymethane (AOM) and dextran sodium sulfate (DSS).
Data combine two independent experiments; total mice, 10 per condition.
k, Spontaneous lung metastases from B16F10 tumours or lung colonization
after B16F10 intravenous injection. Data combine two independent
experiments; total mice, 8 per condition. l, Lung macrometastases from PyMT
tumours. Data combine three independent experiments; total mice:
WTRPyMT, 13; KORPyMT, 16.m, TAN quantification in T241, B16F10,
PyMT, HCC and CRC tumour tissues. Total mice: T241 and CRC, 10 per
condition; B16F10, 8 per condition, combining two experiments;
WTRPyMT, 13; KORPyMT, 16, combining three experiments; HCC, 4 per
condition (one experiment). n, o, B16F10 tumour growth (n), spontaneous
metastases and lung colonization (o) in Mrp8;Metwt/wt and Mrp8;Metfl/fl mice.
Data combine two independent experiments; total mice: Mrp8;Metwt/wt, 12;
Mrp8;Metfl/fl, 8. p, Liver nodules in Mrp8;Metwt/wt and Mrp8;Metfl/fl HCC-
bearing mice. Total mice, 7 per condition. q, TAN quantification in B16F10
tumours (total mice, 8 per condition) or HCCs (total mice, 7 per condition).
r–t, Tumour growth (r), weight (s) and TANs in short hairpin RNA (shRNA)
Met-silenced (shMet) and scrambled B16F10 tumours after PF-04217903 or
vehicle treatment. Data combine two independent experiments (total mice, 11
per condition for scramble; 14 per condition for shMet). *P, 0.05. Scale bars:
0.5 cm (f, g); 200mm (i, j). Graphs show mean6 s.e.m.
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Figure 3 | Met expression in neutrophils is induced by tumour-derived
soluble factors. a, b, Quantitative polymerase chain reaction with reverse
transcription (qRT–PCR) (a) and fluorescence-activated cell sorting (FACS)
(b) analysis for MET in blood neutrophils from tumour (TM)-free or LLC-
tumour-bearing mice and in TANs. c, qRT–PCR forMET in human
neutrophils from lung cancer versus healthy tissue. n5 4 patients. d, e, MET
expression by qRT–PCR (d) and western blot (e) in circulating neutrophils
from tumour-freemice after co-culture with unstimulated (HUVEC/NS) or IL-
1a-pre-stimulated (HUVEC/IL) human umbilical vein endothelial cells
(HUVECs), or after stimulation with TCM or CCM. f, g, qRT–PCR (f) or
western blot (g) for MET in circulating human neutrophils after stimulation
with A549-CCM. h, Western blot for MET in mouse and human neutrophils
after LPS or TNF-a stimulation. i, qRT–PCR for Met in WT, TNFR1 KO or
TNFR2 KOmouse neutrophils after TNF-a stimulation. j, k, qRT–PCR (j) and
western blot (k) forMET inmouse neutrophils after TNF-a stimulationwith or
without NF-kB inhibitor. l, qRT–PCR forMet in mouse neutrophils co-
culturedwithHUVEC/ILor stimulatedwithTCMin the presence or absence of
Enbrel. m, n, FACS for MET in TANs (m) and immunohistochemistry for
Ly6G (n) in LLC tumours after Enbrel. Data combine two independent
experiments; total mice, 5 per condition. All data in a, b, d, f, i, j, l are
representative of two independent experiments using four biological replicates
per condition per experiment. All western blots were repeated three times on
independent biological replicates. Full western blot images are shown in
Supplementary Fig. 1. Loading control in e, h displays tubulin or actin
according to Supplementary Fig. 1. *P, 0.05; {P, 0.05 versus mock (i, l) or
versus untreated (j). Graphs show mean6 s.e.m.
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Figure 4 | MET is required for neutrophil transendothelial migration and
cytotoxicity. a–c, Neutrophil quantification (a) on 12-O-
tetradecanoylphorbol-13-acetate (TPA)-painted ear skin (b, c). Data combine
two independent experiments; total mice: 10 per condition for vehicle; 14 per
condition for TPA. d, FACS analysis for Ly6G1 neutrophils or F4/801
macrophages on peritoneal lavages after zymosan-induced peritonitis. Data are
representative of two independent experiments using 4 mice per condition per
experiment. e, FACS analysis for neutrophil recruitment towards HGF or
CXCL1 in air pouch assays. Data combine three independent experiments; total
mice: 10 per condition. f, Ly6G infiltration in LLC tumours or in TPA-painted
ear skin after anti-HGF. Data combine two independent experiments; total
mice: IgG, 11; anti-HGF, 6. g–i, Neutrophil adhesion to HUVEC/IL (g) and
transendothelial migration in response to HGF (h) or TCM with or without
anti-HGF (i). Data in g–i are representative of three independent experiments
using three biological replicates per condition per experiment. WBCs, white
blood cells. j, k, qRT–PCR for Nos2 in LLC-tumour-associated neutrophils or
macrophages (j) and tumour-derived NO production (k). l–n, Quantification
(l) and representative images (m, n) of 3NT and Ly6G co-stained LLC tumour
sections. DAPI, 49,6-diamidino-2-phenylindole. Data in j–n combine two
independent experiments; total mice: 8 per condition. o, TAN cytotoxicity
against LLC cells with or without L-NMMA. Data are representative of four
independent experiments using three biological replicates per condition per
experiment. p–r, LLC tumour growth (p), weight (q) and TANs (r) after
neutrophil-depleting anti-Ly6G treatment. Data combine two independent
experiments; total mice: 16 per condition. *P, 0.05; {P, 0.05 versus PBS
(e), versus mock (g–i), and versusWTRWT untreated (o). Scale bars: 100mm
(b, c); 20mm (m, n). Graphs show mean6 s.e.m.
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HGF-stimulatedWT but notMetKO neutrophils displayed enhanced
NO release and cytotoxicity, which was abated by L-NMMA
(Extended Data Fig. 8k, l).
We then hypothesized that HGF/MET pathway is key for anti-
tumoural neutrophils only. Neutrophil depletion in WTRWT chi-
maeras did not affect LLC tumour growth, implying that in this
tumour model anti-tumoural and pro-tumoural neutrophils are in
balance (Fig. 4p–r). The same treatment in KORWT mice reduced
tumour growth by 34% (Fig. 4p–r), indicating thatMet deletion inhi-
bits recruitment and activation of cytotoxic, but not of pro-tumoural
neutrophils, which are instead blocked by the anti-Ly6G antibody
(Fig. 4r and Extended Data Fig. 8m).
In sum, we demonstrate that MET is induced by inflammatory
stimuli. This receptor is then required for neutrophil extravasation
to inflamed tissues. Extravasated neutrophils respond to HGF by pro-
ducing cytotoxic nitric oxide (Extended Data Fig. 1). All these steps
restrain non-specific immune reactions to the inflammatory site, pre-
venting damage of healthy organs.
These findings highlight a double-edged role of MET in cancer: on
the one hand, in MET-addicted tumours, this pathway is vital for the
cell cycle and survival2; on the other hand, it promotes anti-tumori-
genic activities in neutrophils. Thus, alternative approaches targeting
MET on cancer cells only, and trials guided by new patient selection
strategieswill be important tomaximize the efficacy ofMET inhibition
in oncological diseases3,4,20.
Finally, given the fact that MET-inhibiting drugs are not associated
with overt toxicity1, MET-targeted therapies might ameliorate the
symptoms of inflammatory disorders inwhich neutrophils are import-
ant for disease pathogenesis21.
Online ContentMethods, along with any additional Extended Data display items
andSourceData, are available in theonline versionof thepaper; referencesunique
to these sections appear only in the online paper.
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METHODS
Animals.TheMet floxedmice, a gift from S. S. Thorgeirsson, were backcrossed in
a C57BL/6 background. The Tie2:Cre and MMTV-PyMT transgenic lines were
obtained fromourmouse facility. TheMrp8:Cremicewere a gift fromC.A. Lowell
and P. Bruhns13,22–26. C57BL/6 mice were purchased from Harlan. TNFR1 KO
mice and TNFR2 KO mice were a gift from C. Libert. The Met floxed mice were
intercrossed for at least two generations with Tie2:Cre or Mrp8:Cre in order to
obtainMetfl/fl Cre-negative (WT) orMetfl/fl Cre-positive (KO) littermates for the
specific promoter. All the experimental procedures were approved by the
Institutional Animal Care and Research Advisory Committee of the KU
Leuven. In all the experiments, mice were gender and age matched (within an
age range between 6 and 10 weeks).
Cell lines. Murine Lewis lung carcinoma cells (LLC), melanoma B16F10, and
human non-small-cell lung carcinoma A549 cells were obtained from the
American Type Culture Collection (ATCC); the murine pancreatic tumour cell
line Panc02 and the murine fibrosarcoma cell line T241 were gifts from U.
Cavallaro and L. Claesson-Welsh, respectively. LLC, B16F10, A549 and T241 cells
were cultured in DMEM (Gibco) supplemented with 2mM glutamine, 100 units
ml21 penicillin, 100mgml21 streptomycin and containing 10% FBS (DMEM 10%
FBS). Panc02 cells were cultured in RPMI (Gibco) supplemented with 2mM
glutamine, 100 unitsml21 penicillin, 100mgml21 streptomycin and containing
10% FBS. All these murine tumour cell lines are syngeneic in a C57BL/6 back-
ground, allowing implantation in Met conditional knockout mice or chimaeras.
HUVECs were isolated from human umbilical cords and maintained in M199
(Invitrogen) supplemented with 20% FBS, 2mM glutamine, 100 unitsml21 peni-
cillin, 100mgml21 streptomycin, 0.15% heparin, 20mgml21 ECGS (M199 com-
plete). 0.1% pork gelatin was used to favour the adhesion of HUVECs to the flask
bottom. All cells were maintained in a humidified incubator in 5% CO2 and 95%
air at 37 uC. Three or four different shRNA lentiviral vectors (Sigma) were used to
silence Met in LLC, B16F10 or T241 cells (LLC shMet, B16F10 shMet or T241
shMet; see later), or to silence TNFA in HUVECs (HUVEC shTNFA). Scramble
lentiviral vectors were used as control. Transduced cells were selected with 8mg
ml21 puromycin. All cancer cell lines and primary HUVECs underwent myco-
plasma testing before their use. Negative mycoplasma contamination status was
verified using LookOut Mycoplasma PCR Kit (Sigma) and MycoAlert
Mycoplasma Detection Kit plus Assay Control (Lonza). Panc02 and T241 cells
were both authenticated by Idexx Bioresearch. All cells were passaged in the
laboratory for no longer than 6months after receipt. Supplementary Table 1 lists
the sequences of all the shRNA constructs used in this study.
Bone marrow transplantation and blood cell count. Recipient 6-week-old
female mice were lethally irradiated (9.5Gy) and then intravenously injected with
107 bonemarrow cells fromWTorKOmice 16 h later. Experiments were initiated
5 weeks after bone marrow reconstitution. Blood cell count was determined using
a haemocytometer on peripheral blood collected by retro-orbital bleeding.
Haematopoietic stem/progenitor cell transduction. ForMEToverexpression or
reconstitution in WT or Met KO neutrophils, respectively, lineage-negative
haematopoietic stem/progenitor cells (HSPCs) were enriched with the mouse
haematopoietic progenitor enrichment kit (Stem Cell Technologies) and checked
for purity by FACS according to the manufacturer’s protocol. 13 106 cellsml21
were pre-stimulated for 5 h with stem span serum-free medium (Stem Cell
Technologies) supplemented with IL-3 (20 ngml21), SCF (100 ngml21), TPO
(100 ngml21) and FLT-3L (100 ngml21) (Promega), and transducedwith 13 108
transducing units (TU)ml21 of a lentiviral vector expressingmouseMet under the
promoter of the human gene S100A8 (Mrp8:Met), which has been engineered for
neutrophil-specific transcriptional targeting, or an empty vector (Mrp8:Empty) as
control. Briefly, the promoter driving Met expression in neutrophils only corre-
sponds to a 3.6 kb DNA fragment encompassing the natural 59 and 39 regulatory
regions but deleted of its exon coding sequences. Hence,Met is under the control
of the 59 and 39 untranslated regions of the human S100A8 gene and other prox-
imal cis regulatory sequences present in the surrogate DNA fragment13,22–26. Ten
hours after the first viral transduction, cells received a second round of their
respective lentiviral vector; 7 h later 13 106 cells were injected via tail vein in
lethally irradiated C57BL/6 recipient mice. A fraction of transduced HSPCs were
cultured and collected after 9 days to measure the number of integrated vector
copies per cell genome (vector copy number (VCN)) by qPCR using custom
TaqManassays specific forHIV gag sequences (AppliedBiosystems), as previously
described27. Standard curves for HIV gag (contained by both Mrp8:Empty and
Mrp8:Met lentiviral vectors) were obtained from the corresponding plasmids.
Fifty nanograms of genomic DNA from each sample were subjected to qPCR in
quadruplicate using an ABI Prism 7500 Fast Real-Time PCR System (Applied
Biosystems). VCN was determined comparing the amplification signal on the
genomic DNA with the standard curve consisting of serial dilutions over a 6 log
range (slope, approximately23.3; intercept, approximately 35; efficiency percent-
age, approximately 100). Average copies per cell genome were calculated taking
into account that one murine diploid genome5 5.92 pg. The results of this ana-
lysis are shown in Supplementary Table 2.
Tumour models. 23 106 LLC or 13 106 B16F10 cells were injected subcuta-
neously while 23 106 T241 cells were injected intradermally in a volume of
200ml PBS. Tumour volumes were measured three times a week with a calliper.
At end stage, tumours were weighed and collected for histological examination or
FACS analysis. MMTV-PyMT1 spontaneous breast tumours were measured 10
weeks after birth (6 weeks after bonemarrow transplantation), three times a week,
andmice were killed at week 16. Lungmetastases were contrasted by intratracheal
injection of a 15% India ink solution, byH&E staining on lung paraffin sections, or
detected by qRT–PCR for the melanoma-specific gene S100B in the models invol-
ving B16F10 cells. For orthotopic pancreatic tumour growth, mice were anaesthe-
tized with isoflurane, the stomach exteriorized via abdominal midline incision,
and 13 106 Panc02 tumour cells in 30ml PBS were injected into the head of the
pancreas using a 29-gauge needle. A successful intrapancreatic injection of tumour
cells was identified by the appearance of a fluid bleb without intraperitoneal
leakage. Mice displaying peritoneal leakage were immediately killed and excluded
from the analysis. At day 12, primary tumours were removed and weighed.
Enlarged lymph nodes were counted under a stereoscopic microscope. For the
chemically induced colorectal cancer model, body-weight-matched mice received
one intraperitoneal injection of 10mgkg21 of azoxymethane (AOM) followed by
3 cycles of 7 days of 1.5% (cycle I) or 1.7% (cycle II–III) dextran sodium sulphate
(DSS) in drinking water, starting from the day of AOM injection28. After 160 days,
the colon was collected and prepared for histological evaluation with the ‘Swiss
roll’ technique29. For the oncogene-driven hepatocellular carcinoma model, mice
received a 1:1 molar ratio (3mg total DNA) of piggyBac transposons encoding for
c-Myc andH-RasG12V oncogenes, driven by the PGK promoter, together with the
hyperactive piggyBac transposase-encoding plasmid30. DNA solutions containing
transposon/transposase plasmids were diluted in 2ml of Ringer’s solution and
hydrodynamically delivered in 7 s through the tail vein. Mice were killed 24 weeks
after the hydrodynamic injection.
Lung colonization assay. In the experimentalmetastasis assays, 0.53 106 B16F10
cells were injected in the tail vein and lungs were collected after 12 days. To
quantify pulmonary seeding, lungs were homogenized in Trizol (Ambion) and
RNA was purified with the RNeasy Mini kit (Ambion) according to manufac-
turer’s instructions. The expression of the melanocyte-specific gene S100B was
measured as a readout of lung colonization by qRT–PCR following reverse tran-
scription to complementary DNA with the QuantiTect Reverse Transcription kit
(Qiagen).
Mice treatments. To induce chronic colitis, mice received 3 cycles of 7 days of
1.5% (cycle I) or 1.7% (cycle II–III) DSS in drinking water; 2 weeks after the last
DSS cycle, the colon was collected and prepared for histological evaluation as
described earlier29. For in vivo MET inhibition, B16F10 tumour-bearing mice
received 40mgkg21 PF-04217903 (AbMole Bioscience) or the corresponding
vehicle (0.5% methylcellulose in saline) via oral gavage every day once a day
starting from day 2 after tumour injection and twice a day from day 11 until the
end of the experiment; alternatively mice were treated with 50mgkg21
INCB28060 (AbMole Bioscience) or 50mgkg21 JNJ-38877605 (Selleckchem).
For TNF-a inhibition in vivo, LLC tumour-bearing mice were randomized for
comparable tumour volumes at the end stage and intraperitoneally (i.p.) injected
with 10mgkg21 of Enbrel or human IgG in PBS, 3 and 1 day before tumour
collection. For HGF inhibition in vivo, LLC tumour-bearing mice were rando-
mized when average tumour volume was 300mm3 and i.p. injected with 0.2mg
permouse of anti-HGFblocking antibody (AF-2207, R&D18,31) or goat IgG in PBS.
Tumours were collected 20 h later for histological analysis; 12-O-tetradecanoyl-
phorbol-13-acetate (TPA) ear painting was done 5 h after antibodies administra-
tion and ears were collected 15 h later. For neutrophil depletion, mice were treated
with 50mg per 20 g body weight of rat anti-mouse Ly6G antibody (clone 1A8,
BioXCell) or rat IgG every second day starting from day 4 after LLC tumour
injection and every day from day 12 after tumour injection until the end of the
experiment. Efficiency of neutrophil depletionwas assessed by FACS in blood and
tumours.
TPA model of acute skin inflammation. Phorbol ester TPA was used to induce
acute skin inflammation as described previously32. Briefly, TPA (2.5mg in 20ml
acetone per mouse) was topically applied on the ear skin of anaesthetized mice.
The contralateral ear was painted with acetone alone as vehicle control. Mice were
killed after 24 h and ears were collected in 2% PFA for histological analysis.
Zymosan-mediated acute peritonitis model. To induce acute peritonitis, zymo-
san A (Sigma) was prepared at 2mgml21 in sterile PBS. Four hours after i.p.
injection of 0.1mg zymosan A per mouse, inflammatory exudates were harvested
by peritoneal lavagewith 2ml PBS. Cells were counted with a Burker chamber and
stained for Ly6G (1A8) and F4/80 (BM8) for FACS analysis.
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Air pouch assay. To create subcutaneous air pouches, bone marrow transplanted
chimaeric mice or Mrp8;Metfl/fl or Mrp8;Metwt/wt mice were injected with 3ml of
sterile air by dorsal subcutaneous injection with a butterfly 23G needle on day 0
and on day 3. On day 6, 200ng per mouse of murine CXCL1 or HGF dissolved in
0.5ml PBS-Heparin (15Uml21) or PBS-Heparin (15Uml21) as control, were
injected in the newly formed dorsal camera. After 4 h, inflammatory cells were
harvested by washing the pouch with 5ml of PBS. Cells were stained for Ly6G
(1A8), washed and resuspended in PBS 0.1% BSA with unlabelled counting beads
and quantified by FACS.
Mouse white blood cell isolation. Bloodwas collected from the retro-orbital vein
in 10% heparin. For the isolation of white blood cells (WBCs), the blood was
diluted in 1.25% dextran in saline to allow the sedimentation of red blood cells
(RBCs). After 30min, the erythrocyte-poor upper layer was collected and washed
in PBS 0.1% BSA. The remaining RBCs were lysed in a hypotonic solution of 0.2%
NaCl for 30 s and brought in isotonic condition with 1.6%NaCl and 0.1% glucose.
WBCs were washed in PBS 0.1% BSA, counted and resuspended accordingly with
the experimental setting.
Mouse blood neutrophil isolation. Blood was collected from the retro-orbital
vein in 10%heparin anddiluted in an equal volume of PBS 0.5%BSA.Up to 5ml of
diluted blood was layered on top of a discontinuous gradient of Histopaque 1119
(4ml) and Histopaque 1077 (5ml) from Sigma. The gradient was centrifuged for
30min at 700g with the brake off. The neutrophil layer between the Histopaque
1077 and 1119 was collected and washed in PBS 0.5% BSA. RBC lysis was per-
formed as described earlier. Neutrophils were washed in PBS 0.5% BSA, counted
and resuspended according to the experimental condition. Alternatively, blood
was sedimented in a saline solution containing 1.25% dextran and neutrophils
were negatively selected with magnetic beads33. Neutrophil purity, as assessed by
the hemocytometer, was always higher than 93%.
Bone marrow neutrophil and mononuclear cell isolation. To reach reasonable
amounts of protein, all the western blot analyses in mice were performed on
neutrophils isolated from bone marrows. Mice were killed by cervical dislocation.
Femurs and tibiaswere collected in cold sterile Hank balanced salt solution (HBSS;
Invitrogen) and flushed with HBSS 0.25% BSA. Cells were layered on top of a
discontinuous gradient of Percoll 81%, 62%, 55%, freshly prepared and centri-
fuged for 30min at 2,000g with the brake off. Monocytes were collected at the
interface between the bone marrow cells and the layer of Percoll 55%, whereas
neutrophils were collected at the interface between Percoll 55% and 62%. Cells
were washed in HBSS 0.25% BSA and RBC lysis was performed as described
earlier. Neutrophils (or monocytes) were washed again, counted and resuspended
according to the experimental setting. Neutrophil (or monocyte) purity, as
assessed using a haemocytometer, was higher than 87%.
FACS analysis and flow sorting of blood or tumour-associated cells. Bloodwas
collected in 10% heparin, incubated for 15min with Mouse BD Fc Block (2.4G2,
BD Pharmingen) 1:100 and stained for 20min at room temperature. After RBC
lysis, cells were washed and resuspended in FACS buffer (PBS containing 2% FBS
and 2mM EDTA). Tumours were minced in RPMI medium containing 0.1%
collagenase type I and 0.2% dispase type I (Gibco) for 30min at 37 uC and passed
through a 70 and 40mm cell strainer. After RBC lysis, cells were resuspended in
FACS buffer. Lungs were collected after 7min of transcardial perfusionwith saline
and processed as for the tumours. Single-cell suspensions were incubated for
15min at 4 uC with Mouse BD Fc Block 1:100 in FACS buffer. The antibodies
were added directly in the blocking solution in the appropriate combinations (as
indicated in the figure legends). CD45 (30F-11), CD11b (M1/70), Ly6G (1A8),
CD45R (RA3-6B2), CD3 (17A2), CD4 (RM4-5), IgE (R35-72), CD49b (DX5),
Ly6C (AL-21) (all from BD Pharmingen), F4/80 (BM8), CD115 (AF598),
MHCII (M5/114.15-12) (all from eBioscience), were used 1:200 for 23 106 in
100ml; Siglec-F (E50-2440, BD Pharmingen) was diluted 1:750. In all the stainings
7AAD (BD Pharmingen) was used to gate out dead cells. For intra-tumour pro-
liferation, 1mg of BrdU was i.p. injected in each mouse 4 h before tumour collec-
tion and cell proliferation was quantified on single-cell suspensions with the FITC
BrdUFlowKit (BDBioscience) according to themanufacturer’s protocol. Tumour
apoptosis was assessed by staining single-cell suspensions for the apoptoticmarker
AnnexinV (1:40, BD Bioscience), excluding 7AAD-positive cells. For TAN apop-
tosis, tumour single-cell suspensions were gated for CD11b (M1/70) and Ly6G
(1A8); AnnexinV and 7ADD were used to distinguish apoptotic or dead neutro-
phils. In vitro neutrophil apoptosis was performed by seeding neutrophils isolated
from tumour-bearing mice at a concentration of 13 106 per ml and stimulating
themwith or without LPS (1mgml21), alone or in combination with HGF (100 ng
ml21) for 10 h at 37 uC.Cells were collected, washed and stained forAnnexinVand
7AAD. The combination of CD11b (M1/70), Ly6G (1A8) andMET (eBioclone 7,
eBioscience, 1:50) was used to identify triple-positiveMET-expressing neutrophils
in blood or 7AAD-negative single-cell suspensions from tumours. Freshly stained
samples were analysed by FACS Canto II (BD Bioscience). For tumour-associated
neutrophil sorting, the myeloid population was enriched by coating with CD11b-
conjugated magnetic beads (MACS, Miltenyi Biotec), followed by separation
through magnetic columns (MACS, Miltenyi Biotec), staining with Ly6G and
sorting with a FACS Aria I (BD Bioscience). Cells were collected in RLT buffer
(Qiagen) for RNA extraction or resuspended according to the experimental con-
ditions.
Humanneutrophil isolation.Tenmillilitres of venous blood fromhealthy volun-
teers were collected in citrate-coated tubes and isolated by erythrocyte sedimenta-
tionwith dextran andpurificationwith a discontinuous plasma-Percoll gradient as
already described34.
Lung cancer patients. We enrolled four non-small-cell lung carcinoma patients
with no previous history of oncological, chronic inflammatory, or autoimmune
diseaseswithin 10 years before this study. This patient list includes 2males (61 and
71 years of age) and 2 females (64 and 68 years of age), of which 3 were smokers
(1 T1N0M0 adenocarcinoma, 1 T2N0M0 large-cell carcinoma, 1 T3N0M0
squamous-cell carcinoma) and 1 was a non-smoker (T2N0M0 adenocarcinoma).
The protocol was approved by the Ethics Committee of the University Hospitals
Gasthuisberg (Leuven), and all subjects consented before study participation.
Flow sorting of neutrophils from lung cancer patients. Lung tumour biopsies or
healthy tissues were minced in RPMI medium containing 0.1% collagenase type I,
0.2% dispase type I and DNase I 100Uml21 (60min at 37 uC), passed through a
19G needle and passed through a 70 and 40mm cell strainer. After RBC lysis, cells
were resuspended in FACS buffer (PBS containing 2% FBS and 2mM EDTA) and
counted. The myeloid population, enriched using CD11b-conjugated magnetic
beads (MACS, Miltenyi Biotec) and separated through a magnetic column
(MACS, Miltenyi Biotec), was stained with anti-CD66b (G10F5, BD Pharmingen,
1:100) for 20min at 4 uC and sorted with FACS Aria I (BD Bioscience). Cells were
counted and resuspended in RLT buffer (Qiagen) for RNA extraction.
Endothelial cell isolation. Lungs were collected and a single-cell suspension was
obtained as described earlier. Endothelial cells were obtained by performing a
negative selection for CD45 (30F-11) and F4/80 (CI:A3-1) followed by a positive
selection for CD31 (MEC 13.3) by using magnetic beads (Dynabeads, Invitrogen)
according to the manufacturer’s protocol.
Peritoneal macrophages. Five millilitres of sterile PBS were injected in the peri-
toneum of anaesthetized mice and collected after 3min. Cells were centrifuged,
washed and cultured overnight.
TCM and LLC (or A549) CCM preparation. Two grams of end-stage LLC
tumour explanted from WT mice were chopped and incubated at 37 uC in 7ml
of DMEM (supplemented with 2mM glutamine, 100 unitsml21 penicillin/100mg
ml21 streptomycin) FBS-free (DMEM 0% FBS). 53 104 LLC (or A549) were
seeded in a 6-multiwell plate in DMEM 10% FBS and incubated at 37 uC.
Medium alone (DMEM 0% FBS or DMEM 10% FBS, respectively) was used to
prepare mock controls. After 72 h, the medium was filtered, supplemented with
2mM glutamine and 20mM HEPES and stored at 220 uC. TCM and mock
medium (DMEM 0% FBS) were diluted 1:5 in DMEM 10% FBS; CCM and mock
medium (DMEM 10% FBS) were diluted 4:5 in DMEM FBS-free.
qRT–PCR. For mRNA analysis, 13 105 or 33 105 mouse or human blood neu-
trophils, respectively, were incubated in normoxic (21% oxygen) or hypoxic (1%
oxygen) conditions, or stimulated with TCM (plus 50mgml21 Enbrel or human
IgG where indicated), CCM, A549-CCM, 100ngml21 of murine or human TNF-
a, 50 ngml21 LPS, or mock medium in a 96-multiwell plate for 4 h at 37 uC. For
NF-kB inhibition, 0.183 106 neutrophils were pre-treated with 10mM 6-amino-
4-(4-phenoxyphenylethylamino) quinazoline (Calbiochem) for 1 h at 37 uC and
stimulated with 100ngml21 of murine TNF-a for 1 h at 37 uC. 23 105 HUVECs
were seeded in a 24-multiwell plate coated with 0.1% gelatin and stimulated with
5 ngml21 IL-1a in DMEM 10% FBS for 4 h at 37 uC. Cells were washed in PBS,
collected in RLT buffer (Qiagen) and kept at 280 uC. RNA was extracted with the
RNeasy Micro kit (Qiagen) according to the manufacturer’s instructions. Reverse
transcription to cDNAwas performed with the SuperScript III First Strand cDNA
Synthesis Kit (Life Technologies) according to the manufacturer’s protocol. Pre-
made assays were purchased from Applied Biosystem, except for Nos2 that was
provided by IDT. cDNA, primer/probe mix and TaqMan Fast Universal PCR
Master Mix were prepared in a volume of 10ml according to manufacturer’s
instructions (Applied Biosystems). Samples were loaded into an optical 96-well
Fast Thermal Cycling plate (Applied Biosystems) and qRT–PCR were performed
using an ABI Prism 7500 Fast Real-Time PCR System (Applied Biosystems)
ELISA. To quantify plasma, intra-tumoural, tumour-released (TCM) and neu-
trophil-released HGF, a murine HGF ELISA kit (R&D) was used according to
manufacturer’s protocols. Blood was collected from tumour-free or tumour-bear-
ing mice and plasma was prepared according to manufacturer’s instruction. TCM
was prepared as described earlier. Tumour proteins were extracted in Extraction
Buffer (20M Tris HCl, 150mM NaCl, 1% Triton X-100, 10% glycerol, 5mM
EDTA). 0.23 106 neutrophils were cultured for 20 h in DMEM complete in
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presence or absence of 100ngml21 ofmurineTNF-a.Mediumwas collected, spun
down and supernatant stored at 280 uC until use. Mock medium was used as
negative control. For phospho-MET quantification, 63 106 mouse blood neutro-
phils isolated from tumour-bearing mice were cultured in the presence or absence
of 100ngml21 of murine TNF-a; 11 h later, cells were stimulated or not with
100ngml21 of mouse HGF in the presence of 1mM orthovanadate for 3min at
37 uC, washed in PBS supplemented with 1mM orthovanadate and 13 phosStop
(Roche) and lysed in Extraction Buffer supplemented with 1mM orthovanadate,
23 phosStop andCompleteMini protease inhibitor cocktail (Roche) for 20min at
4 uC. After clearance, samples were quantified and the same amount of proteins
was used for MET and phospho-MET detection using a sandwich ELISA. Briefly,
96-well microtitre plates (MaxiSorp, Nunc) were coated with 1mgml21 of anti-
mouse MET antibody (AF527, R&D Systems) overnight at 4 uC and then incu-
bated for 2 h at room temperature in blocking buffer (PBS, 0.1% Tween-20, 6%
non-fat dry milk). The same amount of proteins per sample was diluted in block-
ing buffer and incubated for 2 h at room temperature on the ELISA plate. After 6
washes in PBS 0.1% Tween-20, samples were incubated for 2 h at room temper-
ature with the mouse anti-MET (3D4, Invitrogen) or the mouse anti-phosphotyr-
osine (4G10, Merck Millipore) antibodies diluted 1:500 in blocking buffer, then
washed 6 times in PBS 0.1% Tween-20, and incubated with goat anti-mouse
immunoglobulins conjugated to horseradish peroxidase (sc-2031, Santa Cruz
Biotechnology) diluted 1:500 in blocking buffer for 2 h at room temperature.
Signals were developed by 15min incubation with the 3,39,5,59-tetramethylbenzi-
dine (TMB) substrate solution (Promega). After stopping the reactionwithH2SO4,
absorbance was measured at 450nm and corrected for 630nmwith a spectropho-
tometer.
Western blot.To assessMET deletion, bonemarrow cells, neutrophils, peritoneal
macrophages,monocytes (all cultured overnight in TCM) or endothelial cells were
lysed in hot Laemmli buffer (2.5% SDS, 25%Tris-HCl pH 6.8) for 10min at 96 uC,
sonicated, cleared and quantified. Alternatively, 23 106 bone-marrow-derived
neutrophils from WT mice were stimulated with TCM, CCM, 100ngml21 of
murine TNF-a (or mock medium 0% FBS or 10% FBS as control) for 20 h at
37 uC. For the co-culture with HUVECs, a monolayer of HUVECs was stimulated
for 4 h with 5 ngml21 IL-1a at 37 uC, and washed before neutrophil seeding. After
20 h of stimulation, neutrophils were collected using Cell Dissociation Buffer
Enzyme Free PBS-Based (Gibco). Cells were washed in PBS, lysed in 15ml of a
protease inhibitormixture and incubated for 15min on ice. The protease inhibitor
mixture was obtained by dissolving one tablet of CompleteMini protease inhibitor
mixture (Roche) in 5ml of PBS with 2mM diisopropyl fluorophosphate (DFP;
Acros Organics). After addition of an equal amount of 23 SDS sample buffer
supplemented with 4% 2-mercaptoethanol, the lysates were boiled for 15min and
kept at 280 uC until use. NF-kB inhibition was achieved by pre-treating 73 106
neutrophils with 10mM 6-amino-4-(4-phenoxyphenylethylamino) quinazoline
(Calbiochem) for 1 h at 37 uC; cells were then stimulated with murine TNF-a
(100 ngml21) for 5 h before lysis. Human MET was assessed by stimulating
33 107 blood neutrophils isolated from the blood of healthy volunteers with
A549-CCM, 100ngml21 human TNF-a, 50 ngml21 LPS (or mock medium
10% FBS as control) for 20 h. Cells were incubated with 2.7mM DFP for 15min
at 4 uC, collected and washed in PBS supplemented with 2.7mM DFP and
Complete Mini protease inhibitor 13, and lysed in hot Laemmli buffer at 96 uC
for 10min. Cell lysates were sonicated, cleared and quantified. 63 loading buffer
was added before loading on the gel. The following primary antibodies were used:
mouse anti-mouse Met (3D4, Invitrogen), mouse anti-mouse b-actin (I-19, Santa
Cruz),mouse anti-vinculin (hVIN-1, Sigma), rabbit anti-humanMET(D1C2,Cell
Signaling), horseradish peroxidase (HRP)-conjugated anti-b-tubulin (Abcam).
The following secondary antibodies were used: HRP-conjugated goat anti-mouse
and HRP-conjugated goat anti-rabbit (Santa Cruz). Signal was visualized by
Enhanced Chemiluminescent Reagents (ECL; Invitrogen) or West Femto by
Thermo Scientific according to the manufacturer’s instructions.
Adhesion assay. 43 104HUVECswere seeded inM199 complete in a 96-multiwell
plate, previously coated with 0.1% gelatin. After 12 h, HUVECs were stimulated
with 5 ngml21 IL-1a in DMEM 10% FBS at 37 uC. After 4 h the endothelial
monolayer was gently washed and 2.53 105 WBCs were isolated indistinctly
fromTie2;Metwt/wt andTie2;Metfl/flmice or fromWTRWTandKORWT trans-
plantedmice, were seeded on top of it, with or withoutmurineHGF (50 ngml21).
After 15min non-adherent cells were washed out whereas adherent cells were
detached by using a Cell Dissociation Buffer Enzyme Free PBS-Based (Gibco).
Cells were stained for Ly6G (clone 1A8), washed and resuspended in PBS-BSA
0.1% with unlabelled counting beads (BD Bioscience) and quantified by FACS
Canto II (BD Bioscience).
Transmigration and migration assay. For the transmigration assay, 23105
HUVECs were seeded on 3mm polycarbonate membrane (Transwell; Costar) prev-
iously coated with 0.1% gelatin in M199 complete. After 12h, HUVECs were
stimulated for 4 h at 37 uC in DMEM 10% FBS with 5ngml21 IL-1a and then
washed. 53 105WBCs isolated indistinctly fromTie2;Metwt/wt andTie2;Metfl/flmice
or from WTRWT and KORWT transplanted mice were seeded on top of the
endothelial monolayer, while mock medium, TCM (with or without 3mgml21
anti-HGF antibody AF-2207; R&D)18,31 or 50 ngml21 murine HGF was added in
the bottom. After 2 h at 37 uC, transmigrated cells were collected from the bottom
chambers and from the lower side of the filter with cold PBS 0.5% EDTA. Cells were
stained and Ly6G1 cells were quantified as described earlier. In the migration assays
WBCs were seeded directly on top of 3mm polycarbonate porous membranes.
Nitric oxide measurement by FACS.Neutrophils isolated from the blood ofWT
or KO LLC-tumour bearing mice were co-cultured for 4 h with LLC shMet,
washed and resuspended in 20mM HEPES-PBS, and incubated for 10min with
5mMDAF-FM diacetate (Molecular Probes) in the absence or presence of mouse
HGF (100 ngml21) at 37 uC. Cells were then washed and analysed by FACS.
Cytotoxicity assay. LLC shMet or T241 shMet were transduced with a luciferase-
expressing lentiviral vector (EX-hLUC-Lv114 from GeneCopoeia); 104 cells were
then seeded in DMEM 10% FBS in a 96-multiwell plate. After 4 h, 0.23 106 neu-
trophils purified from the blood of tumour-bearing mice or directly from the
tumours themselves, were co-cultured with the cancer cells in DMEM 2% FBS
for 4 h at 37 uC, with or without 100 ngml21 mouse HGF or 1mM L-NMMA
(Sigma). After washing, adherent cells were lysed in 0.2% Triton, 1mM dithio-
threitol (DTT). Luciferase signal was revealed with a microplate luminometer. The
use of shMet was thought to prevent any possible confounding activity of MET on
cancer cell survival and thus to restrict the effect of HGF to neutrophils only.
Histology and immunostainings. To obtain serial 7-mm-thick sections, tissue
sampleswere immediately frozen inOCTcompoundor fixed in 2%PFAovernight
at 4 uC, dehydrated and embedded in paraffin. Paraffin slides were first rehydrated
to proceed further with antigen retrieval in citrate solution (DAKO). Cryosections
were thawed in water and fixed in 100% methanol. If necessary, 0.3% H2O2 was
added to methanol to block endogenous peroxidases. The sections were blocked
with the appropriate serum (DAKO) and incubated overnight with the following
antibodies: rat anti-CD45 (30F-11, BD Pharmingen) 1:100, rat anti-Ly6G (1A8,
BD Pharmingen) 1:100, rat anti-CD31 (MEC 13.3, BD Pharmingen) 1:200, rabbit
anti-FITC (Serotec) 1:200, goat anti-phosphohistoneH3 (Cell Signaling) 1:100, rat
anti-F4/80 (CI:A3-1, Serotec) 1:100, mouse anti-NK1.1-biotin (PK136, BD
Pharmingen) 1:200, rat anti-CD45R (RA3-6B2, BD Pharmingen) 1:100, rat
anti-CD4 (H129.9, BD Pharmingen) 1:100, rat anti-CD8 (53-6.72, BioXCell)
1:100, hamster anti-CD11c biotin (N418, eBioscience) 1:100, mouse anti-3-nitro-
tyrosin (HM.11 Santa Cruz) 1:200. Appropriate secondary antibodies were used:
Alexa488-or Alexa568-conjugated secondary antibodies (Molecular Probes)
1:200, HRP-labelled antibodies (DAKO) 1:100, Biotin-labelled antibodies
(Jackson ImmunoResearch) 1:100. When necessary, tyramide signalling amp-
lification (Perkin Elmer, Life Sciences) was performed according to the manufac-
turer’s instructions. Whenever sections were stained in fluorescence, ProLong
Gold mounting medium with DAPI (Invitrogen) was used. Otherwise, 3,39-dia-
minobenzidine was used as a detection method followed by Harris’ haematoxilin
counterstaining, dehydration and mounting with DPX. Apoptotic cells were
detected by the TUNEL method, using the AptoTag peroxidase in situ apoptosis
detection kit (Millipore) according to the manufacturer’s instructions. For the
double staining TUNEL and Ly6G, TUNEL staining was performed as described
earlier, followed by Ly6G staining by using the Vectastain ABC kit (Vector
Laboratories) according to the manufacturer’s instructions. Tumour necrosis
and lung metastasis were evaluated by H&E staining. Necrotic area was defined
as the area including necrotic cancer cells, inflammatory cells and stromal cells,
compared to the total area of the field. Necrotic cells display a more glassy homo-
geneous appearance in the cytoplasm with increased eosinophilia, while the nuc-
lear changes are reflected by karyolysis, pyknosis and karyorrhexis. Alternatively,
the necrotic tissue was visualized by autofluorescence as previously described35.
Microscopic analysis was done with anOlympus BX41microscope andCell Sense
imaging software or a Zeiss Axioplan microscope with KS300 image analysis
software. The morphometric analysis was performed by acquiring 4–6 fields per
section on five independent sections (at a distance of 40mm in depth during
sectioning) from the same biological tissue sample. The values in the graphs
represent the average of the means of at least five samples and the standard error
indicates the variability among the different samples.
Hypoxia assessment and tumour perfusion. Tumour hypoxia was detected by
injection of 60mgkg21 pimonidazole into tumour-bearing mice 1 h before
tumour harvesting. To detect the formation of pimonidazole adducts, tumour
cryosections were immunostained with Hypoxyprobe-1-Mab1 (Hypoxyprobe
kit, Chemicon) following themanufacturer’s instructions. Perfused tumour vessels
were counted on tumour cryosections from mice injected intravenously with
0.05mg fluorescein isothiocyanate (FITC)-conjugated lectin (Lycopersicon escu-
lentum; Vector Laboratories).
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Tumour-derived nitric oxide production. LLC tumours were collected 8 days
after injection, cut in pieces of about 53 5mm,weighted and incubated at 37 uC in
a 24-multiwell plate with 800ml of DMEM. After 24 h, the media was collected,
centrifuged to remove cell debris, and NO levels were measured using the Griess
reagent system kit (Promega).
Statistics. Data entry and all analyses were performed in a blinded fashion. All
statistical analyses were performed using GraphPad Prism software. Statistical
significance was calculated by two-tailed unpaired t-test on two experimental
conditions or two-way analysis of variance (ANOVA) when repeated measures
were compared, with P, 0.05 considered statistically significant. Data were tested
for normality using the D’Agostino–Pearson omnibus test (for n. 8) or the
Kolmogorov–Smirnov test (for n# 8) and variation within each experimental
group was assessed. Detection of mathematical outliers was performed using the
Grubbs’ test in GraphPad. Sample sizes for all experiments were chosen based on
previous experiences. Independent experiments were pooled and analysed
together whenever possible as detailed in figure legends. All graphs show mean
values6 s.e.m.
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Extended Data Figure 1 | Scheme illustrating the role of MET in
neutrophils. During cancer or infections, the release of cytokines such as IL-1
at the inflammatory site will promote the expression of TNF-a on the
endothelium and the surrounding tissue. When circulating neutrophils
encounter the activated endothelium, TNF-a will unleash NF-kB through
binding toTNFR1, which in turnwill induceMET expressionon the neutrophil
surface. HGF, also released and proteolytically activated at the site of
inflammation, will bind toMET and stimulate the firm adhesion of neutrophils
to the endothelium, probably via integrin engagement, and thus neutrophil
diapedesis. Once extravasated, the HGF/MET pathway will still function on
neutrophils by reinforcing their cytotoxic response through the induction
of iNOS and NO production, ultimately favouring a bactericidal and
tumoricidal neutrophil phenotype.
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Extended Data Figure 2 | Met deletion in immune cells, but not in
endothelial cells, fosters tumour growth. a, MET expression in total bone
marrow (BM) cells, endothelial cells (EC) and neutrophils harvested fromMet
floxed mice intercrossed with the Tie2:Cre deleter thus generating Tie2;Metfl/fl
(KO) or Tie2;Metwt/wt (WT) mice. Western blots are representative of three
repetitions on independent biological replicates. Western blot images have
been cropped for presentation. Full scan images are shown in Supplementary
Fig. 1. b–d, Quantification (b) and representative images of tumour sections’
TdT-mediated dUTP nick end labelling (TUNEL) stainings (c, d) from
subcutaneous end-stage LLC tumours in WTRWT and KORWTmice. Data
combine two independent experiments; total n5 10 mice per condition.
e, FACS quantification of AnnexinV1 7AAD2 early apoptotic tumour cells in
WTRWT and KORWT mice. Data combine two independent experiments;
total n5 8 mice per condition. f–j, Tumour necrosis quantification in
WTRWT and KORWTmice (f), assessed by histological evaluation of H&E-
stained tumour sections (g, h) and by measurement of autofluorescent tumour
areas (i, j); yellow dotted lines demarcate necrosis. Data combine two
independent experiments; total n5 10 mice per condition.
k–m, Quantification (k) and representative images of tumour sections stained
for the proliferation marker pHH3 (l, m) from subcutaneous end-stage LLC
tumours in WTRWT and KORWT mice. Data combine two independent
experiments; total n5 10mice per condition.n, FACS quantification of BrdU1
proliferating tumour cells in WTRWT and KORWT mice. Data combine
two independent experiments; total n5 10 mice per condition. o–r, CD311
vessel area (o), vessel density (p), lectin perfusion (q) and hypoxic (Pimo1)
area (r) in LLC subcutaneous tumours from KORWT mice (in which the
haematopoietic/immune system is knocked out forMet) or WTRKO mice
(in which endothelial cells only are knocked out forMet) compared to
control WTRWT mice. Data in o–r combine two independent
experiments; total n: WTRWT, 12; KORWT,8; WTRKO, 8.
s–u, Subcutaneous LLC tumour growth (s), weight (t) and lung
metastases (u) in Tie2;Metfl/fl compared to Tie2;Metwt/wt mice. Data combine
two independent experiments; total n: Tie2;Metwt/wt, 12;
Tie2;Metfl/fl, 10. v, Subcutaneous LLC tumour growth in endothelial-cell-
specificMetKO (WTRKO) and control (WTRWT)mice. Data combine two
independent experiments; total n5 8 per condition. *P, 0.05 versus
WTRWT (b, e, f, k, n), versus Tie2;Metwt/wt (s–u). Scale bars: 50mm
(c, d, l, m); 100mm (g–j). All graphs show mean6 s.e.m.
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ExtendedData Figure 3 | Circulating and tumour-infiltrating immune cells
upon Met deletion. a–e, FACS analysis showing percentages of
circulating monocytes (a), lymphocytes (b), neutrophils (c), eosinophils
(d) and basophils (e) in tumour-free or in LLC-tumour-bearing WTRWT
and KORWT mice. Data combine two independent experiments; total n5 8
mice per condition. f, Quantification of LLC tumour sections stained for the
pan-leukocyte marker CD45, the macrophage marker F4/80, the NK marker
NK1.1, the B lymphocyte marker CD45R, the T helper cell marker CD4, the
cytotoxic T cell marker CD8 and the dendritic cell marker CD11c (with
exclusion of F4/801 area) inWTRWTandKORWTmice. Data combine two
independent experiments; total n5 8 mice per condition). g, h, FACS
quantification for tumour-associated CD451 leukocytes (g) or CD451 IgE1
CD49b1CD42CD45R2 basophils andCD451CD11b1 SiglecF1Ly6Cmed F4/
80low MHCII2 eosinophils (h) in WTRWT and KORWT mice.
Data combine two independent experiments; total n5 8 mice
per condition. i, j, FACS quantification (i) and gating strategy (j) for
tumour-associated neutrophils selected from the main tumour cell population
negative for 7AAD staining; tumour-associated neutrophils were then gated as
CD11b and Ly6G double-positive cells. Data combine two independent
experiments; total n: WTRWT, 11; KORWT,10. k, Ly6G1 tumour
infiltration at day 9, day 13 and day 19 after LLC subcutaneous tumour
injection in WTRWT and KORWT mice. Data combine two independent
experiments; total n5 8mice per condition. l, Morphometric quantification of
leukocytes and macrophages on CD45- and F480-stained lung sections,
respectively, from LLC-tumour-bearing WTRWT or KORWT mice. Data
combine two independent experiments; total n5 8 mice per condition.
m, FACS quantification of CD11b1 Ly6G1 neutrophils and CD11b1 F4/801
macrophages infiltrating metastatic lungs from LLC-tumour-bearing
WTRWT or KORWT mice. Data combine two independent experiments;
total n5 8 mice per condition. *P, 0.05 versus WTRWT
(f, g, i, k–m); {P, 0.05 versus tumour free (a–d). All graphs show
mean6 s.e.m.
LETTER RESEARCH
G2015 Macmillan Publishers Limited. All rights reserved
RESEARCH LETTER
G2015 Macmillan Publishers Limited. All rights reserved
Extended Data Figure 4 | MET in neutrophils is required for their anti-
tumour activity. a, b, Western blot analysis (a) and relative densitometric
analysis (b) for MET expression in bone marrow neutrophils and monocytes
upon reconstitution ofWT recipient mice byWT or KOHSPCs transduced in
vitrowith an empty vector (Mrp8:Empty) or a vector expressingMet under the
neutrophil-specific promoter Mrp8 (Mrp8:Met); tubulin was used as loading
control. Western blots are representative of three repetitions on independent
biological samples where each sample is the pool of neutrophils or monocytes
isolated from three mice. Densitometric analysis was performed on these three
western blots. A.U., arbitrary units. c, FACS analysis for green fluorescent
protein (GFP) in circulating Ly6G1 neutrophils or CD1151 monocytes,
harvested from the neutrophil-specific Mrp8:Cre line carrying separate
expression of GFP because of an internal ribosome entry site (IRES)
downstream the Mrp8-driven cre gene. Data combine two independent
experiments; total n5 10 mice per condition. d, MET expression in
neutrophils, monocytes and macrophages harvested from Mrp8;Metwt/wt or
Mrp8;Metfl/fl mice. Western blots are representative of three repetitions on
independent biological replicates. e, FACS analysis for CD11b1 Ly6G1
neutrophils in subcutaneous LLC tumours from Mrp8;Metwt/wt or
Mrp8;Metfl/fl. Data combine two independent experiments; total n:
Mrp8;Metwt/wt, 10; Mrp8;Metfl/fl, 11. Western blot images in a, d have been
cropped for presentation. Full scan images are shown in Supplementary Fig. 1.
*P, 0.05 versus Mrp8:Empty WTRWT (b), versus Mrp8;Metwt/wt
(e); {P, 0.05 versus Mrp8:Empty WTRWT; {P, 0.05 versus Mrp8:Empty
KORWT. All graphs show mean6 s.e.m.
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Extended Data Figure 5 | Pharmacological and genetic inhibition of MET
prevents the recruitment of anti-tumoural neutrophils to several neoplastic
tissues and inflammatory sites. a, Tumour weight of subcutaneous B16F10
melanomas inWTRWT and KORWTmice. Data combine two independent
experiments; total n: WTRWT, 8; KORWT,9. b, c, Total tumour weight
(b) and metastatic index (c) in MMTV-PyMT mice reconstituted with WT or
Met KO bone marrow cells before tumour appearance (WTRPyMT and
KORPyMTmice, respectively).Data combine three independent experiments;
total n: WTRPyMT, 13; KORPyMT, 16. d, e, FACS quantification for
CD11b1 Ly6G1 neutrophils in T241 tumours harvested from WTRWT or
KORWT mice (d) or in in breast tumours spontaneously grown in
WTRPyMT and KORPyMT mice (e). Data combine two independent
experiments; total n5 10 mice per condition (d) or total n5 8 mice per
condition (e). f–i, Length measurement (f) and representative image (g) of the
colon, aswell as quantification of neutrophils (h) andmacrophages (i) on bowel
sections, fromWTRWTandKORWTmice upon induction of chronic colitis
compared to healthy control. Data combine two independent experiments;
total n: healthy, 5; WTRWT,12; KORWT,15. j, k, Tumour weight (j) and
metastatic mesenteric lymph nodes (k) 12 days after orthotopic injection of
pancreatic Panc02 cancer cells inWTRWTandKORWTmice.Data combine
two independent experiments; total n5 12 per condition. l, Histological
quantification of Ly6G1 infiltrates in Panc02 pancreatic tumours harvested
from WTRWT and KORWT mice. Data combine two independent
experiments; totaln5 12mice per condition.m, Quantificationof plasmaHGF
in tumour (TM)-freemice, in subcutaneous LLCor orthotopic Panc02 tumour-
bearing mice. Data combine two independent experiments; total n: tumour
free, 10; LLC, 10; Panc02, 8 biological replicates. n, Quantification of HGF in
subcutaneous LLC or orthotopic Panc02 tumours. Data combine two
independent experiments; total n: LLC, 10; Panc02, 8 biological replicates.
o, p, Quantification of HGF in plasma (o) or in subcutaneous LLC tumours
(p) from tumour-bearing WTRWT and KORWT mice. Data are
representative of two independent experiments using 5 mice per condition per
experiment. q, Quantification of Ly6G1 area on sections from B16F10
melanomas grown in C57BL/6 WT mice, daily treated with PF-04217903,
INCB28060, JNJ-38877605, or vehicle as control. Data combine two
independent experiments; total n: vehicle, 14; PF-04217903, 9; INCB28060, 6;
JNJ-38877605, 4. r, Western blot analysis for MET in B16F10 melanoma cells
after transduction with a lentiviral vector encoding scrambled or mouse shMet
under a constitutive promoter; vinculin was used as loading control. Western
blot is representative of three independent repetitions. Western blot images
have been cropped for presentation. Full scan images are shown in
Supplementary Fig. 1. *P, 0.05 versusWTRWT(a,d, h), versusWTRPyMT
(b, e), versus LLC (m, n), versus vehicle (q); {P, 0.05 versus healthy
(f, h, i), versus tumour free (m). Scale bar: 10mm (g). All graphs show
mean6 s.e.m.
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Extended Data Figure 6 | HGF is required for MET activation upon
induction by TNF-a. a, Gating strategy related to Fig. 3b to quantify MET
expression in blood neutrophils from LLC-tumour (TM)-bearing mice and in
TANs, where live cells were first gated as CD11b-positive cells; this population
was finally gated for Ly6G and MET to identify MET-expressing Ly6G1
neutrophils. b, c, qRT–PCR forMET in mouse (b) and human (c) neutrophils
after LPS or TNF-a stimulation. Data are representative of three independent
experiments using four biological replicates per condition per experiment.
d, e, qRT–PCR for MET expression in mouse (d) or human (e) neutrophils
cultured in normoxia (21% O2) or hypoxia (1% O2). Data combine two
independent experiments; total n5 8 biological replicates per condition.
f, g, ELISA for total MET (f) and phospho-MET (g) from mouse neutrophils
stimulated for 3min with mockmedium or HGF after an overnight incubation
with or without TNF-a. Data combine three independent experiments; total
n5 6 biological replicates per condition. h, HGF release by neutrophils
stimulated with mock medium or TNF-a after 20 h in culture. Data combine
two independent experiments; total n5 6 biological replicates per condition.
i, qRT–PCR for TNFA in HUVECs upon stimulation with IL-1a compared to
mock medium. Data combine two independent experiments; total n5 4
biological replicates per condition. j, qRT–PCR forMet in mouse neutrophils
co-cultured with HUVEC/NS or HUVEC/IL transduced with shTNFA or
scramble as control. Data are representative of three independent experiments
in which three different shRNA sequences were used; total n5 4 biological
replicates per condition per experiment. k, l, qRT–PCR forMet inWT, TNFR1
KO or TNRF2 KO neutrophils upon co-culture with HUVEC/NS or HUVEC/
IL (k), or after stimulation with conditioned medium (TCM) from LLC
tumours (l). Data are representative of two independent experiments using four
biological replicates per condition per experiment.m, qRT–PCR forMET in
human neutrophils stimulated with A549-CCM in the presence or absence of
Enbrel or human IgG as control. Data are representative of two independent
experiments using four biological replicates per condition per experiment.
*P, 0.05 versus mock (b, c, i), versus TNF-a alone (g), versus HUVEC/NS
(j), versus WT (k, l), versus A549-CCM (m); {P, 0.05 versus untreated or
HGF alone (f, g), versus HUVEC/NS (k), versus mock (l, m). Graph shows
mean6 s.e.m.
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Extended Data Figure 7 | Met deletion in neutrophils does not affect
apoptosis. a, b, Gating strategy of apoptotic WT (a) andMet KO
(b) neutrophils in LLC tumours where single-cell suspensions were first gated
for physical parameters and then for CD11b and Ly6G to identify neutrophils
as double-positive cells; this population was finally gated for AnnexinV and
7AAD: AnnexinV1 7AAD2 cells display early apoptotic neutrophils whereas
AnnexinV1 7AAD1 cells display late apoptotic neutrophils. c, Quantification
of apoptotic WT andMet KO tumour-associated neutrophils measured by
FACS. Data combine two independent experiments; total n5 7 mice per
condition. d, Quantification of apoptotic WT andMet KO neutrophils on LLC
tumour sections by immunohistochemistry. Data combine two independent
experiments; totaln:WTRWT, 7; KORWT,6. e, FACSanalysis forAnnexinV
and 7AAD of WT or KO neutrophils incubated for 10 h in the presence or
absence of LPS and HGF, alone or in combination. Data combine two
independent experiments; total n5 6 biological replicates per condition.
{P, 0.05 versus untreated or HGF alone. Graph shows mean6 s.e.m.
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Extended Data Figure 8 | MET affects neither neutrophil basal migration
nor polarization but it is required for neutrophil recruitment and
cytotoxicity. a, Quantification of Ly6G staining in ear sections upon phorbol
ester (TPA)-induced cutaneous rash in Mrp8;Metwt/wt and Mrp8;Metfl/fl mice.
Data combine two independent experiments; total n5 8 mice per condition.
b, FACS analysis on peritoneal lavages for Ly6G1 neutrophils or F4/801
macrophages in Mrp8;Metwt/wt and Mrp8;Metfl/fl mice 4 h after
intraperitoneal injection of sterile zymosan A. Data are representative of two
independent experiments using 5 mice per condition per experiment.
c, d, Quantification of F4/80 (c) and CD3 (d) stainings in ear sections at
baseline and upon TPA-induced cutaneous rash. Data combine two
independent experiments; total n: WTRWT control (CTRL), 22; KORWT
CTRL, 15; WTRWT TPA, 23; KORWT TPA, 15 (c); or total n5 8 mice per
condition (d). e, FACS quantification of Mrp8;Metwt/wt and Mrp8;Metfl/fl
neutrophils recruited into subcutaneous air pouches in response to HGF,
CXCL1 or PBS. Data combine two independent experiments; total n5 6
mice per condition. f, FACS quantification of WT neutrophil adhesion to
quiescent HUVECs (HUVEC/NS) or activated HUVECs (HUVEC/IL) in the
presence or absence of HGF. Data are representative of two independent
experiments using four biological replicates per condition per experiment.
g, h, FACS quantification of WT and Met KO neutrophils migrated through
a bare porous filter (that is, in the absence of HUVECs) towards HGF (g) or
tumour conditioned medium (TCM) (h). Data are representative of two
independent experiments using three biological replicates per condition per
experiment. i, Gene expression profile for N1 and N2 markers in
neutrophils sorted from LLC tumours grown in WTRWT or KORWT
mice. Data are representative of three independent experiments using 4
mice per condition per experiment. j, Cytotoxicity of WT and KO
tumour-associated neutrophils against T241 cells in the absence or
presence of the NO synthase inhibitor L-NMMA. Data are representative
of three independent experiments using three biological replicates per
condition per experiment. k, FACS quantification of DAF-FM-positive
circulating neutrophils after co-culture with LLC cancer cells as a readout
of NO production in the absence or presence of HGF. Data are
representative of four independent experiments using three biological
replicates per condition per experiment. l, Quantification of LLC cancer
cell killing by WT and KO neutrophils (isolated from the blood of
tumour-bearing mice), stimulated with HGF alone or in the presence of
L-NMMA. Data are representative of two independent experiments using
n5 12 biological replicates per condition per experiment. m, Blood
neutrophils in WTRWT and KORWT mice treated with neutrophil-
depleting Ly6G antibody or rat IgG as control. Data combine two
independent experiments; total n5 16 per condition. *P, 0.05 versus
Mrp8;Metwt/wt (a, b), versus Mrp8;Metwt/wt 1 HGF (e), versus HUVEC/
NS (f), versus WTRWT untreated (j), versus WTRWT 1 HGF
(k,l); {P, 0.05 versus CTRL (c, d), versus PBS (e), versus mock
(f, h), versus WTRWT untreated (j–l), versus IgG (m); {P, 0.05 versus
WTRWT 1 HGF (l). All graphs show mean6 s.e.m.
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Extended Data Table 1 | Blood count in Tie2;Metwt/wt or Tie2;Metfl/fl tumour-free mice
Tumour free Tie2;Metwt/wt Tie2;Metfl/fl 
WBC (k/µl) 5.68±1.44 5.55±1.29 
NEU (%) 23.03±5.45 29.67±7.88 
LYM (%) 69.72±6.46 72.03±4.89 
MON (%) 1.24±0.37 2.86±1.15 
EOS (%) 0.12±0.05 0.17±0.12 
BAS (%) 3.38±1.32 4.47±2.1 
RBC (M/µL) 5.21±1.91 4.89±1.52 
HCT (%) 71.3±3.43 60.2±13.38 
MCHC (g/dl) 15.83±2.65 18.3±0.26 
PLT (K/µL) 439.73±26.64 508±55.79 
The values show the haematological parameters (mean6 s.e.m.) in tumour-free Tie2;Metwt/wt and Tie2;Metfl/flmice. Data combine two independent experiments; total n510 per condition. BAS, basophil; EOS,
eosinophil; HCT, haematocrit; LYM, lymphocyte; MCHC, mean cell haemoglobin concentration; MON, monocyte; NEU, neutrophil; PLT, platelet; RBC, red blood cell; WBC, white blood cell.
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Extended Data Table 2 | Blood count in WTRWT and KORWT tumour-free or tumour-bearing mice
The values show the haematological parameters (mean6 s.e.m.) in tumour-free or LLC-tumour-bearing (21 days)WTRWTandKORWTchimaericmice. Data combine two independent experiments; total n510
per condition. BAS, basophil; EOS, eosinophil; HCT, haematocrit; LYM, lymphocyte; MCHC,mean cell haemoglobin concentration; MON,monocyte; NEU, neutrophil; PLT, platelet; RBC, red blood cell; WBC, white
blood cell.
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